1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Algeria Pharmaceuticals and Healthcare Report Q2 2016

Algeria Pharmaceuticals and Healthcare Report Q2 2016

  • February 2016
  • -
  • Business Monitor International
  • -
  • 89 pages

Includes 3 FREE quarterly updates


BMI View:
Despite a slowdown in the Algerian economy due to low oil prices, the country's pharmaceutical and healthcare markets are expected to sustain their positive growth trajectory over a multi-quarter horizon. The health sector expansion will be supported by long-term drivers such as growing demand for healthcare and treatment, healthcare system modernisation and sustained foreign investment in domestic drug manufacturing. Although we expect foreign investors to continue benefitting from government incentives aimed at boosting domestic pharmaceutical production and technology transfer, operating challenges will continue weigh on the market's full potential.


Headline Expenditure Projections
- Pharmaceuticals: DZD411.62bn (USD4.12bn) in 2015 to DZD451.90bn (USD4.13bn) in 2016; +9.8% in local currency and +0.3% in US dollar terms. Forecast in line with last quarter.
- Healthcare: DZD1,113.59bn (USD11.13bn) in 2015 to DZD1,204.64bn (USD11.00bn) in 2016; +8.2% in local currency and -1.2% in US dollar terms. Forecast revised upwards in local currency terms and downwards in US dollar terms from last quarter.

Table Of Contents

Algeria Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View ... 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Algeria 2014-2020) . 7
SWOT 9
Industry Forecast .. 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Algeria 2012-2020) 13
Healthcare Market Forecast .. 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Algeria 2012-2020) . . 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Algeria 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Algeria 2012-2020) . . 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Algeria 2012-2020) . . 19
Patented Drug Market Forecast . 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Algeria 2012-2020) 21
Generic Drug Market Forecast .. 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Algeria 2012-2020) . 23
OTC Medicine Market Forecast . 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Algeria 2012-2020) . . 25
Pharmaceutical Trade Forecast . 26
Table: Pharmaceutical Trade Data And Forecasts (Algeria 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Algeria 2014-2020) . . 28
Industry Risk/Reward Index . 29
Middle East and Africa Risk/Reward Index - Q2 2016 . 29
Algeria Risk/Reward Index 36
Rewards ... 36
Risks 37
Regulatory Review 38
Intellectual Property Issues .. 42
Pricing Regime .. 45
Reimbursement Regime ... 45
Market Overview ... 47
Healthcare Sector .. 48
Research and Development 50
Clinical Trials ... 52
Epidemiology 53
Competitive Landscape 56
Research-Based Industry . 56
Table: Multinational Market Activity . 58
Generic Drugmakers .. 59
Pharmaceutical Distribution 60
Pharmaceutical Retail . 61
Company Profile 62
GlaxoSmithKline . 62
Groupe Saidal . 64
Merck and Co 68
Novartis . 70
Pfizer 72
Sanofi 74
Demographic Forecast . 78
Demographic Outlook .. 78
Table: Population Headline Indicators (Algeria 1990-2025) 79
Table: Key Population Ratios (Algeria 1990-2025) . 79
Table: Urban/Rural Population and Life Expectancy (Algeria 1990-2025) . . 80
Table: Population By Age Group (Algeria 1990-2025) 80
Table: Population By Age Group % (Algeria 1990-2025) 81
Glossary . 83
Methodology .. 85
Pharmaceutical Expenditure Forecast Model .. 85
Healthcare Expenditure Forecast Model . 85
Notes On Methodology 86
Risk/Reward Index Methodology ... 87
Index Overview .. 88
Table: Pharmaceutical Risk/Reward Index Indicators . 88
Indicator Weightings .. 89

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.